

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT INCLUSION OF FOUR INNOVATIVE DRUGS INCLUDING NEW INDICATIONS IN THE UPDATED NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce the following 4 innovative drugs including new indications of the Group have been included in the updated National Reimbursement Drug List (“**NRDL**”) released by China’s National Healthcare Security Administration:

- Aumolertinib mesylate tablets (trade name: Ameile 阿美樂®), a Category 1.1 innovative drug researched and developed by the Group, is included in the updated NRDL for its newly approved indication and its approved indication:
 - For the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“**NSCLC**”) whose tumors have epidermal growth factor receptor (“**EGFR**”) exon 19 deletions or exon 21 (L858R) mutations (new indication approved in 2021);
 - For the second-line treatment of adult patients with locally-advanced or metastatic EGFR T790M mutation-positive NSCLC, whose disease has progressed on or after EGFR-TKI therapy (indication approved in 2020 and included in the NRDL since 2021).
- Inebilizumab Injections (trade name: XINYUE 昕越®) is included in the updated NRDL for its approved indication:
 - For the treatment of adult patients with neuromyelitis optica spectrum disorders (“**NMOSD**”) who are anti-aquaporin-4 (“**AQP4**”) immunoglobulin G seropositive (indication approved in 2022).

- The updated NRDL will continue to include flumatinib mesylate tablets (trade name: Haosen Xinfu 豪森昕福®) and PEG-loxenatide for injection (trade name: Fulamei 孚來美®).

The inclusion of the above four innovative drugs into the updated NRDL will help the Group to further enhance the affordability and accessibility of each innovative drug among patients.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, January 18, 2023

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.